Glaxosmithkline Biologicals Sa

Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Novartis Vaccines and Diagnostics Srl

Domenico Maione

Guido Grandi

Paolo Costantino

Immaculada Margarit Y Ros

Cira Daniela Rinaudo

John Telford

Francesco Berti

Mario Contorni

Nathalie Norais

Francesco Doro

Oretta Finco

Roberta Cozzi

Sabrina Liberatori

Immaculada Margarit Ros

Cira Daniela Rinuado

Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from(GBS) serotypes conjugated to carrier proteins.

Immunogenic composition

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a BP-2a antigen and a spb1 antigen. BP-2a and spb1 areantigens. The conjugate may be used in a method for raising an immune response in a mammal, the method comprising administering the conjugate to the mammal. Also provided are pharmaceutical compositions, particularly vaccines, comprising the conjugate.

Carrier molecule for antigens

The invention provides proteins and compositions for the treatment and prevention of(Group B; GBS).

Immunogenic proteins and compositions

The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype Ia conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein; d) a conjugate that is a capsular saccharide from GBS serotype II conjugated to a carrier protein; and e) a conjugate that is a capsular saccharide from GBS serotype V conjugated to a carrier protein.

The invention provides an immunogenic composition comprising one or more GBS conjugates and one or more antigens selected from: a) cellular or acellular pertussis antigen, b) a tetanus toxoid, c) a diphtheria toxoid and d) an inactivated polio virus antigen, wherein each GBS conjugate is a group Bcapsular saccharide conjugated to a carrier protein. The invention also provides a method for raising an immune response in a patient, comprising the step of administering to the patient a composition of the invention.

Immunogenic compositions

[object Object]

This application relates to Group B('GBS') vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.

The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group Bserotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.

The invention provides protective antigens for Group Bhypervirulent strains. The fragments are useful in vaccine compositions to induce protection against, particularly against hypervirulent strains.

Growing community of inventors

Siena, Italy

Domenico Maione